Overview

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2023-06-19

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free survival after daratumumab maintenance therapy in transplant eligible participants with previously untreated Multiple Myeloma.

Phase:

Phase 3

Details

Lead Sponsor:

Intergroupe Francophone du Myelome

Collaborators:

HOVON - Dutch Haemato-Oncology Association
Janssen Research & Development, LLC

Treatments:

Antibodies, Monoclonal
BB 1101
Bortezomib
Daratumumab
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Thalidomide